Jake Morgan

$NRED is taking a very different path now New CEO Valentin Saitarli brings an AI and computer vision background, while the company shifts toward MetalCore,mining robotics and automation This is starting to look more like a mining-tech story than a traditional junior miner $CAT

The bigger picture behind the latest $RYET news is much larger than one Malaysia agreement AI in healthcare is becoming a global industry. Current market estimates put the sector at roughly $56B in 2026, with forecasts reaching around $1 TRILLION by 2034. That is the market backdrop for RYET latest move. Ruanyun announced a definitive agreement involving Cogni AI and BioNexus Gene Lab in Malaysia, giving its AI technology a path into healthcare rather than keeping it limited to education and enterprise applications. The structure is interesting too: an exclusive license framework of up to 20 years, 10% royalty economics on qualifying technology receipts, and 560K BGLC shares at closing. For me, this is what makes the news important. RYET is not suddenly becoming a healthcare giant. It is testing whether Cogni AI can be licensed into a completely different industry and international market while that industry itself is experiencing massive AI adoption. Education was the starting point. Enterprise AI expanded the story. Now healthcare adds another potential use case. If Cogni AI can continue moving across industries and markets, that becomes a much more interesting business model than relying on one product or one sector. Malaysia may be only the first healthcare test, but it puts RYET directly in front of one of the fastest-growing global technology trends.

$RYET is lighting up the Discord scanner right now RYET just announced a Malaysia healthcare deal with BioNexus for Cogni AI The Discord scanner is now flagging bullish momentum as traders react to the news Fresh catalyst + fresh volume = one to watch closely today

BREAKING: $RYET is expanding into Malaysian healthcare 🇲🇾 Ruanyun/Formind announced an exclusive Cogni AI licensing agreement with Nasdaq-listed BioNexus Gene Lab, opening a completely new healthcare vertical for the company. Key terms: • Exclusive Cogni AI license for up to 20 years • 10% royalty on qualifying technology receipts • 560,000 BGLC shares to RYET at closing • Focus on AI-powered healthcare applications in Malaysia BioNexus operates in genomic screening and precision healthcare, giving Cogni AI a potential path into real healthcare workflows This comes as $RYET is already expanding beyond its original education business into AI platforms, Smart Campus services and international markets. Education. Enterprise AI. Now healthcare Malaysia is becoming a much bigger part of the Formind expansion story.

What keeps $RYET on my radar isn’t the hype. It’s the change in the numbers A year ago this was a tiny story with limited scale. Now preliminary H1 FY2027 revenue is expected at $9.3M-$9.5M That’s a very different setup I’m not interested in chasing a headline. I’m watching whether the company can prove this growth is repeatable and turn it into stronger margins, more contracts and a bigger operating base That’s where the real story starts for me

This is the $RYET update I wanted to highlight again Preliminary H1 FY2027 revenue is expected at $9.3M-$9.5M, versus only about $0.37M in H1 FY2026 And that six-month figure already exceeds the company’s $7.48M FY2026 full-year revenue That is a major change in operating scale Preliminary and unaudited, but the revenue growth is now the main story to watch nitter.cf/TradePulse2/status/210…

The latest $RYET numbers are hard to overlook Expected H1 FY2027 revenue is $9.3M-$9.5M, while H1 FY2026 was only about $0.37M That is a massive change in revenue scale in just one year

The YeeZo detail matters for $RYET RMB5.99M contract Delivered Accepted by the customer There’s a big difference between announcing a project and actually completing one Execution is what turns a microcap story into a business